GSG Advisors LLC Grows Stake in Bioventus Inc. (NYSE:BVS)

GSG Advisors LLC increased its holdings in shares of Bioventus Inc. (NYSE:BVS) by 55.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,511 shares of the company’s stock after purchasing an additional 9,500 shares during the quarter. GSG Advisors LLC’s holdings in Bioventus were worth $133,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new stake in shares of Bioventus during the fourth quarter worth about $85,000. Jump Financial LLC purchased a new stake in shares of Bioventus during the fourth quarter worth about $122,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Bioventus during the fourth quarter worth about $145,000. Barclays PLC purchased a new stake in shares of Bioventus during the third quarter worth about $119,000. Finally, Citigroup Inc. grew its position in shares of Bioventus by 13,474.4% during the third quarter. Citigroup Inc. now owns 52,533 shares of the company’s stock worth $173,000 after purchasing an additional 52,146 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BVS shares. Craig Hallum increased their price target on Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Canaccord Genuity Group increased their price target on Bioventus from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th.

Bioventus Price Performance

Bioventus stock traded up $0.07 during midday trading on Friday, reaching $5.67. 497,255 shares of the stock traded hands, compared to its average volume of 323,991. The stock’s fifty day moving average is $5.60 and its 200-day moving average is $5.17. Bioventus Inc. has a 12 month low of $2.70 and a 12 month high of $7.04. The stock has a market cap of $448.89 million, a P/E ratio of -16.20 and a beta of 0.89. The company has a quick ratio of 0.97, a current ratio of 1.53 and a debt-to-equity ratio of 1.63.

Bioventus (NYSE:BVS) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.12. The company had revenue of $129.46 million during the quarter, compared to analyst estimates of $115.51 million. Bioventus had a positive return on equity of 11.91% and a negative net margin of 4.14%. As a group, equities research analysts anticipate that Bioventus Inc. will post 0.27 EPS for the current year.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.